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 Abstract 
 Background: A new fl ow cytometric (FC) BCR-ABL immu-
nobead assay has been developed recently. Here we present 
the laboratory evaluation of the commercially available kit. 
 Methods: Mononuclear cells were isolated, lysed and pro-
cessed according to the instructions of the manufacturer. 
Anti-BCR antibodies adsorbed to capture beads bind the 
BCR-ABL fusion proteins of the lysed cells, a phycoerythrin 
(PE)-conjugated anti-ABL antibody is the detector reagent 
and mean fl uorescence intensity (MFI) signals were recorded 
by fl ow cytometry. Detection of t(9;22)(q34;q11) transloca-
tion was carried out with a quantitative PCR assay. 
 Results: MFI results of 20 normal peripheral blood samples 
were 88 ± 8 (mean ± SD), CV 9 % . K562 cells were used as pos-
itive control. Within-batch imprecision was excellent (3.7 % 
in the normal and 10 % in the pathological range). Cut-off was 
chosen at MFI 112, where both sensitivity and specifi city were 
100 % . Altogether 17 chronic myeloid leukemia (CML) and 
16 acute leukemia samples were analyzed. All PCR positive 
samples (n = 14) were positive with the FC method and nega-
tive results were also concordant (n = 15). Frozen cell lysates 
can be stored up to 4 weeks without signifi cant decrease of 
MFI signal. 
 Conclusions: The FC BCR-ABL assay is a fast, reproducible 
and reliable method that may be incorporated into standard 
fl ow cytometric protocols to help clinical decision-making. 
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 The  BCR-ABL fusion gene can be detected in chronic myeloid 
leukemia (CML), in 2 % – 5 % of childhood and 30 % – 35 % of 
adult acute lymphoblastic leukemia (ALL) cases  (1) . Intro-
duction of tyrosine kinase inhibitors (TKI) into the treatment 
of CML and Ph + ALL have profoundly changed the prognosis 
of these diseases  (2 – 4) . In adult patients diagnosed with Ph + 
ALL, chemotherapy combined with TKI represents the current 
standard of care with newly diagnosed disease. This makes 
detection of  BCR-ABL aberrations of utmost importance.
Detection of t(9;22) is generally carried out at the chromo-
some level using karyotyping or fl uorescence in situ hibrid-
ization (FISH) or at the mRNA level using PCR techniques. 
These methods require specialized laboratories and well-
trained personnel, furthermore they are time-consuming. The 
turn-around-time (TAT) for FISH and PCR techniques is 2 – 3 
days while that of karyotyping is 1 – 2 weeks. Soon after the 
fi rst attempt to detect chromosome translocations with bead-
based fl ow cytometry  (5) a new, rapid method has been devel-
oped to detect the BCR-ABL oncoprotein  (6) . 
 While the  ABL gene contains one large breakpoint region, 
three breakpoint regions [major breakpoint cluster region 
(M- bcr ), minor breakpoint cluster region (m- bcr ) and micro 
breakpoint cluster region ( µ - bcr )] and several additional rare 
breakpoints have been found in the  BCR gene. As a result 
several different fusion transcripts and fusion proteins can 
be formed. The immunoassay was developed to detect all 
possible variants of the BCR-ABL oncoprotein. The BCR-
ABL Protein Kit was fi rst tested in a multicenter study on 
145 BM or PB samples of patients suspected to have CML 
or acute leukemia and PB of 72 healthy individuals. In this 
study Weerkamp et al. found full concordance between the 
PCR and the Protein Kit results when a mean fl uorescence 
intensity (MFI) cut-off of 135 was chosen  (6) . Raponi 
et al. investigated 101 samples of acute leukemia patients 
and concluded that PCR and FC results were concordant in 
all de novo cases but two patients who were pretreated with 
steroid and had  < 10 % blasts showed negative FC and posi-
tive PCR results  (7) . Recently D ’ Alessio et al. described the 
miniaturization of the FC immunobead assay and detected 
the BCR-ABL protein in cerebrospinal fl uid  (8) . Cools and 
Vandenberghe suggested incorporating the new FC test into 
a diagnostic algorithm of hematological malignancies  (9) . In 
the near future several other bead-based immunoassays will 
be developed in order to detect fusion oncoproteins in a few 
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hours and fulfi l clinical needs according to modern standards 
 (10, 11) . 
 The aim of this study was to evaluate the imprecision of the 
new test in normal and pathological ranges and to determine 
the cut-off MFI that dicriminates between PCR positive and 
negative samples. We also determined diagnostic sensitivity 
and specifi city, as well as the stability of the positive signal in 
cell lysates over 5 months. 
 EDTA-anticoagulated peripheral blood (PB) of 20 healthy 
volunteers and PB and bone marrow (BM) aliquots from the 
remnant of the diagnostic sample of 33 hematological patients 
(17 with CML and 16 with acute leukemia) were investigated. 
Mononuclear cells were separated and a standardized amount 
of cells (2.5 × 10 6 ) was lysed and processed according to the 
instructions of BCR-ABL Protein Kit (Becton Dickinson, San 
Jose , CA, USA). Anti-BCR antibodies adsorbed to capture 
beads bind the BCR-ABL fusion proteins and a phycoerythrin 
(PE)-conjugated anti-ABL antibody is the detector reagent  (6) . 
 To enable comparison between different days, BD 
FACSCanto II fl ow cytometer was calibrated daily using 
Calibrite fl uorescent microbeads (Cat No. 641,319, Becton 
Dickinson, San Jose , CA, USA) and Autocomp software as 
recommended by the manufacturer. After the capture beads 
have been identifi ed and gated on the basis of their scatter 
and fl uorescence characteristics, the presence of sandwich 
complexes could be detected by PE (FL2) MFI signals gener-
ated by the detector reagent. Data were recorded and analyzed 
with a FACSDiva software (Becton Dickinson, San Jos e , CA, 
USA). Samples lacking the BCR-ABL fusion protein gave a 
negative signal (Figure  1 A) while K562 cell line, containing 
the oncoprotein gave intensely positive signal (Figure 1B). 
 Detection of t(9;22)(q34;q11) translocation was carried 
out with a quantitative PCR assay [Light Cycler t(9;22) 
Quantifi cation Kit, Roche Diagnostics, Basel, Switzerland] 
 (12) standardized internationally in the EUTOS program. 
Thirteen out of 14 PCR positive samples were analyzed with 
nested PCR according to a standard protocol  (13) . 
 Cell lysates of pooled normal WBC and K562 cells diluted 
to have MFI value slightly above cut-off (MFI 138), another 
with MFI 500 and four patient ’ s peripheral blood mononu-
clear cells (PBMC) were stored at  – 80 ° C and thawed after 
1 day (n = 5); 3 days (n = 2), 1 week (n = 1); 4 weeks (n = 8); 
16 weeks (n = 1) and 20 weeks (n = 3). Statistical analysis was 
performed with GraphPad Prism 4.0 software. 
 Lysates from normal peripheral leukocytes (WBC) and 
from the K562 cell line were used as negative and posi-
tive control, respectively. Mean PE (FL2) MFI of 20 nor-
mal PB samples processed and measured on 20 consecutive 
days was 88 ± 8 (mean ± SD), between-run precision CV was 
9 % . Within-run precision was carried out on a pool of nor-
mal PB samples isolated in one step, then lysed and labeled 
separately. Eight samples were processed and acquired, with 
3.7 % CV. Within-run precision in the pathological range was 
investigated on K562 cell lysates (n = 6), mean MFI 3958, SD 
397, CV 10 % . 
 Altogether 17 CML and 16 acute leukemia patient samples 
(PB and BM) of de novo cases were analyzed. Among acute 
leukemia samples 14 were cALL, one de novo AML and one 
AML transformed from CML. All PCR positive samples 
(n = 14) were found to be positive with the FC method and 
negative results were also concordant (n = 15) (Figure  2 A). In 
the positive samples nested PCR detected six cases with b2a2, 
fi ve cases with b3a2 and two cases with e1a2 rearrangement, 
while nested PCR was not performed in one cALL sample. 
MFI of the positive samples ranged from 118 to 4905 but no 
correlation could be demonstrated between the MFI values 
and the quantitative PCR results (data not shown). Parallel 
examination of PB and BM samples (in four patients) showed 
concordant results in the FC test. In these four cases PCR was 
performed only from PB. 
 Performing a ROC analysis area under the curve was 1.0, 
sensitivity and specifi city of the test was 100 % (CI 95 % ) 
when the cut-off was set at MFI 112, which was the mean 
MFI + 3SD of 20 normal WBC samples. As traditional ROC 
curve was defi nitely a 90 ° -broken line, we demonstrated the 
determination of the cut-off MFI, sensitivity and specifi city 
on one graph (Figure 2B). It shows that lowering the cut-off 
to MFI 95 resulted in 60 % specifi city and elevating it to MFI 
703 decreased the sensitivity to 57 % . 
 Investigation of the stability of fusion protein in frozen 
cell lysates showed no signifi cant loss of the positive signal 
slightly above cut-off level. After 4 weeks fl uorescent signal 
decreased by 1.5 % , even after 20 weeks it decreased by 5.8 % . 
The higher the MFI of the fresh K562 lysate the greater loss 
of MFI could be detected. When MFI was 500 of the fresh 
sample, 15 % signal loss was detected after 4 weeks and 28 % 
after 20 weeks (Figure 2C). The same phenomenon could be 
observed in case of patient samples. No loss of the fl uorescent 
signal was detected in the negative cases while 38 % and 43 % 
MFI loss was found in the positive cases, as the MFI value of 
their fresh sample was very high [737, 3212]. Based on these 
results we recommend storing frozen cell lysates for not more 
than 4 weeks. 
 In conclusion, the fl ow cytometric BCR-ABL assay can 
detect all forms of the BCR-ABL fusion protein in 4 h with 
 Figure 1  Representative histograms of a negative and a positive 
sample. 
 (A) Samples lacking the BCR-ABL fusion protein resulted in a nega-
tive signal while (B) K562 cell line, containing the oncoprotein gave 
positive signal. 
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 Figure 2  Laboratory evaluation of the fl ow cytometric BCR-ABL bead-based immunoassay. 
 (A) Assay results of different sample groups (normal, chronic myeloid leukemia and acute leukemia patients, K562 cells). Mean fl uorescence 
intensity (MFI) is shown on y-axis, horizontal line indicates cut-off at MFI 112. Black-fi lled circles indicate positive, open circle negative result 
with a quantitative PCR method, in case of gray-fi lled circles PCR was not performed. (B) Sensitivity and specifi city of the test was 100 % when 
cut-off was at MFI 112. Lowering cut-off level decreased specifi city, while elevating it decreased sensitivity. (C) Investigation of the stability 
of fusion protein in frozen cell lysates showed no signifi cant loss of the positive signal slightly above cut-off level (K562dil). The higher the 
MFI of the fresh K562 lysate the greater loss of MFI could be detected. When MFI was 500 of the fresh sample, 15 % signal loss was detected 
after 4 weeks and 28 % after 20 weeks. 
high sensitivity and specifi city. In our study in the FC positive 
samples which were tested with nested PCR the three most 
frequent rearrangement types were found. Cut-off should be 
determined in each laboratory as the mean MFI + 3SD of 20 
normal WBC lysates. Frozen cell lysates can be stored up to 4 
weeks without the decrease of fl uorescent signal. 
 Flow cytometry has long been a hallmark of the diagnosis 
of hematological malignancies, mainly to identify the malig-
nant clone and characterize it by the detection of surface and 
intracellular proteins. In a diagnostic setting the short turn-
around time, ease and specifi city of the new BCR-ABL FC 
assay makes it a candidate to be part of an algorithm of inves-
tigation of de novo, untreated patients. Based on the result 
of the FC assay PCR and FISH techniques can be rationally 
triggered. Moreover, it may serve as a molecular diagnosis 
in geographical areas where PCR technique is not available. 
This rapid, simple and reliable fl ow cytometric method opens 
a novel targeted diagnostic and therapeutic approach for the 
management of Ph  +  ALL patients. We recommend its incor-
poration into standard fl ow cytometric protocols in order to 
help clinical decision-making. 
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